Angiotensin II antagonists?saralasin
| Autor: | Robert W. Fulton, Alan F. Moore |
|---|---|
| Rok vydání: | 1984 |
| Předmět: |
medicine.medical_specialty
Angiotensin receptor Angiotensin II receptor type 1 biology Angiotensin-converting enzyme Pharmacology Partial agonist Angiotensin II chemistry.chemical_compound Endocrinology chemistry In vivo Internal medicine Drug Discovery Renin–angiotensin system medicine biology.protein Saralasin |
| Zdroj: | Drug Development Research. 4:331-349 |
| ISSN: | 1098-2299 0272-4391 |
| DOI: | 10.1002/ddr.430040309 |
| Popis: | Saralasin is the only marketed member of a class of compounds described as angiotensin II receptor antagonists. Its pharmacology is characterized by three general properties: (1) no actions unrelated to the renin-angiotensin system; (2) a small partial agonist effect in some tissues in vitro and in some animal models in vivo, and (3) a blood-pressure lowering response to saralasin evident only in animals with an activated endogenous renin angiotensin system. It is suggested that the natriuretic effect of angiotensin II mediated via central nervous system (CNS) mechanisms may be future productive area of research in which to study the actions of angiotensin II antagonists. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text